title: Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome.
abstract: The aim of this study was to evaluate the prognostic value of brain natriuretic peptide (BNP) in outpatients with the Eisenmenger syndrome (ES). BNP is often elevated in patients with cyanotic congenital heart disease. The clinical utility of BNP in patients with cyanotic congenital heart disease and the ES has not been clearly delineated. Records of adults with ES who had undergone serum BNP measurement were reviewed. The primary end point was death or heart failure admission. Fifty-three patients were included, with 15 patients (28%) meeting the primary end point (death in 7, heart failure hospitalization in 8). Mean and median baseline BNP in patients meeting the primary end point were 322 ± 346 and 179 pg/ml, compared to 100 ± 157 and 41 pg/ml in those not meeting the primary end point (p = 0.0029). A Cox proportional-hazards model using baseline BNP between the 2 groups yielded a hazard ratio of 1.84 (95% confidence interval [CI] 1.19 to 2.85, p = 0.006). The relative risk for baseline BNP level >140 pg/ml was 4.62 (95% CI 1.80 to 11.3, p = 0.008). Patients who met the primary end point increased their BNP levels by 42.5 pg/ml per year (95% CI 12.09 to 72.95, p = 0.006) compared to 7.2 pg/ml per year (95% CI 2.01 to 12.47, p = 0.007) in patients who did not meet the primary end point. In conclusion, elevated BNP levels are predictive of death or heart failure admission in patients with the ES. A serum BNP level >140 pg/ml is a useful tool in identifying high-risk patients.
authors.affiliation: Ahmanson/UCLA Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
authors.forename: Leigh C
authors.initials: LC
authors.lastname: Reardon
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Williams
authors.forename: Linda S
authors.initials: LS
authors.lastname: Houser
authors.forename: Pamela D
authors.initials: PD
authors.lastname: Miner
authors.forename: John S
authors.initials: JS
authors.lastname: Child
authors.forename: Jamil A
authors.initials: JA
authors.lastname: Aboulhosn
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D002140:California / Q000453:epidemiology; D018450:Disease Progression; D004541:Eisenmenger Complex / Q000097:blood* / Q000150:complications / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D015994:Incidence; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012720:Severity of Illness Index; D015996:Survival Rate / Q000639:trends
chemical_list: D015415:Biomarkers; D020097:Natriuretic Peptide, Brain